SITC Updates

2026 ASCO Annual Meeting Scientific Highlights - June 2

By Thomas Martin posted 2 days ago

We are pleased to present highlights of the latest advances in immunotherapy emerging from the 2026 ASCO Annual Meeting, June 2, 2026. (Thanks to Chinmay Jani, MD and Terri Holzen, PhD for compiling these scientific highlights) Fitness-enhanced CEA-targeting CAR T cells for advanced colorectal cancer with peritoneal metastases 3514. Phase 1 study of intraperitoneal fast-manufactured IL-9-secreting CEACAM5-targeted CAR T cells in advanced colorectal cancer with peritoneal metastases Hangyu Zhang (The First Affiliate Hospital, Zhejiang University School of Medicine, Hangzhou, China) presented safety and preliminary efficacy data from ...

2026 ASCO Annual Meeting Scientific Highlights - June 1

By Thomas Martin posted 3 days ago

We are pleased to present highlights of the latest advances in immunotherapy emerging from the 2026 ASCO Annual Meeting, June 1, 2026. (Thanks to Chinmay Jani, MD and Terri Holzen, PhD for compiling these scientific highlights) Live biotherapeutic CBM588 improves the clinical efficacy of immune checkpoint blockade-based therapies as first-line treatment for metastatic renal cell carcinoma 4519. Microbial dysbiosis as predictor of benefit from CBM588 as an adjunct to immune checkpoint blockade-based first line therapies in metastatic renal cell carcinoma Rahul Winayak (City of Hope Comprehensive Cancer Center, Duarte, ...

2026 ASCO Annual Meeting Scientific Highlights - May 31

By Thomas Martin posted 4 days ago

We are pleased to present highlights of the latest advances in immunotherapy emerging from the 2026 ASCO Annual Meeting, May 31, 2026. (Thanks to Chinmay Jani, MD and Terri Holzen, PhD for compiling these scientific highlights) Final safety, efficacy and biomarker results from the first-in-human study of oncolytic virus RP2 alone and in combination with nivolumab for advanced solid tumors 2504. RP2 oncolytic immunotherapy alone and in combination with nivolumab (nivo) in patients with advanced solid tumors: Final safety, efficacy, and biomarker results from the phase 1 first-in-human (FIH) study Joseph J. Sacco (The Clatterbridge ...

Immune Monitor - May 2026

By SITC Communications posted 4 days ago

A Message from the President The pace of discovery in cancer immunotherapy continues to accelerate, creating both extraordinary opportunity and an urgent need for collaboration. For more than 40 years, the Society for Immunotherapy of Cancer (SITC) Annual Meeting has helped drive these conversations by convening the global immuno-oncology community around the latest advances in science, translational research, and clinical development. SITC 2026 , our 41 st Annual Meeting and Pre-Conference Programs, will be held Nov. 4̶–8 in Phoenix, AZ and virtually. SITC 2026 will bring together researchers, clinicians, government and industry leaders for an ...

2026 ASCO Annual Meeting Scientific Highlights - May 30

By Thomas Martin posted 5 days ago

We are pleased to present highlights of the latest advances in immunotherapy emerging from the 2026 ASCO Annual Meeting, May 30, 2026. (Thanks to Chinmay Jani, MD and Terri Holzen, PhD for compiling these scientific highlights) Tumor-specific MHC-II as a prospective biomarker of response to perioperative chemoimmunotherapy for gastric cancer 2513. Perioperative tislelizumab plus chemotherapy versus chemotherapy in MHC-II positive /MHC-II negative locally advanced GC/GEJC: A prospective randomized, open-label, biomarker-driven, phase 2 trial Xiangdong Cheng, MD (Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, China) presented ...

2026 ASCO Annual Meeting Scientific Highlights - May 29

By Thomas Martin posted 6 days ago

We are pleased to present highlights of the latest advances in immunotherapy emerging from the 2026 ASCO Annual Meeting, May 29, 2026. (Thanks to Chinmay Jani, MD and Terri Holzen, PhD for compiling these scientific highlights) Azer-cel, an allogeneic CAR T cell, for relapsed or refractory CD19 + B cell malignancies 7012. Safety and efficacy of Azer-cel, an allogeneic CD19 CAR T for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia not previously exposed to autologous CAR T therapy Supriya Gupta (University of Minnesota, Minneapolis, MN, USA) reported results from a phase ...

SITC Signs onto ACS CAN Letter Urging Protection of the USPSTF

By SITC Advocacy posted 8 days ago

The Society for Immunotherapy of Cancer (SITC) joined more than 60 cancer patient and provider organizations in signing onto a coalition letter led by the American Cancer Society Cancer Action Network (ACS CAN) directed to Secretary Kennedy in support of protecting the scientific integrity and evidence-based work of the U.S. Preventive Services Task Force (USPSTF). View the letter in it's entirety at this LINK . View a press release from ACS CAN at this LINK . The USPSTF plays a critical role in cancer prevention and early detection by developing evidence-based recommendations for preventive services, including screenings for breast, cervical, ...

NEW! The Role of Local Immunotherapy in the Treatment of Cancer

By JITC Publications posted 9 days ago

Edited by Tanja D. de Gruijl, PhD and Howard Kaufman, MD, FACS While local immunotherapy has the potential to deliver high doses of immune potentiating agents with limited systemic toxicity, clinical development and implementation have been hindered by numerous challenges. This special series addresses the potential promise of local immunotherapy and provides guidance on how to overcome current challenges in local drug development. Authored by leading experts, “The Role of Local Immunotherapy in the Treatment of Cancer” covers various aspects of local immunotherapy and expands upon the topics and concepts presented in the SITC “ Summit on Intralesional ...

SITC Signs onto OVAC Letter Supporting Timely Cancer Research Funding

By SITC Advocacy posted 14 days ago

The Society for Immunotherapy of Cancer (SITC) joined more than 50 organizations through One Voice Against Cancer (OVAC) in signing a coalition letter to Congress raising concerns about delays and disruptions in federal cancer research funding. View the letter in its entirety at this LINK . The letter, addressed to House and Senate appropriators, expresses appreciation for bipartisan support of the National Institutes of Health (NIH) and the National Cancer Institute (NCI) while highlighting concerns about the slow pace of grant awards, reduced competing grants tied to expanded multi-year funding, and a decline in Notice of Funding Opportunities (NOFOs). ...

SITC 2026 Keynote and Registration Press Release

By Thomas Martin posted 16 days ago

SITC Announces Keynote Speakers Dr. Ton Schumacher and Dr. Catherine J. Wu at its 41 st Annual Meeting The largest cancer immunotherapy conference featuring the latest research in immuno-oncology MILWAUKEE, WI – The Society for Immunotherapy of Cancer (SITC) is proud to announce Ton Schumacher, PhD from the Netherlands Cancer Institute as the Keynote Speaker at its 41 st Annual Meeting and Pre-Conference Programs (SITC 2026) with his presentation “T Cell Recognition of Human Cancer: 'Cracking the Code' ”. SITC also hosts Catherine J. Wu, MD from the Dana-Farber Cancer Institute as the 2026 recipient of the Richard V. Smalley Memorial ...

JITC Digest May 2026

By JITC Publications posted 16 days ago

INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks| JITC Meet-the-Editor Session at ASCO| Popular Articles Letter from the Editor Hello JITC Readers, This last month on April 29 th we celebrated with the International Union of Immunological Societies (IUIS) International Day of Immunology . On this day, they focused on regulatory T cells (Tregs) and their role in cancer as well as other immunologic settings. This is timely given the recent Nobel Prize in Physiology or Medicine awarded in late 2025 to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their work identifying and ...

Immune Monitor - April 2026

By SITC Communications posted 22 days ago

A Message from the President Staying current in immuno-oncology has never been more important—or more complex. With rapid advances across research, clinical practice, and regulation, access to timely, trusted education is essential. That’s where our brand-new Society for Immunotherapy of Cancer (SITC) OnDemand comes in. SITC OnDemand offers a robust, library of expert-led education designed to fit your schedule . Subscribers can access recorded sessions from SITC meetings and programs featuring cutting-edge science, clinical insights, and translational research. Whether you’re catching up on a missed session or revisiting key content, OnDemand helps ...

SITC Signs onto ASGCT Letter Supporting Cancer Research Funding

By SITC Advocacy posted 24 days ago

As Congress begins deliberations on Fiscal Year 2027 (FY27) appropriations, continued investment in the National Institutes of Health (NIH) remains essential to sustaining progress in biomedical research and innovation. The Society for Immunotherapy of Cancer (SITC) is proud to join a stakeholder letter led by the American Society of Gene & Cell Therapy (ASGCT) advocating for strong federal support for NIH funding in FY27. View the letter in its entirety here . The letter calls on lawmakers to provide at least $51.303 billion in funding for NIH and to ensure that appropriated funds are distributed in a timely manner once enacted. Stable and predictable ...

2026 AACR Annual Meeting Scientific Highlights

By Thomas Martin posted 04-23-2026

We are pleased to present highlights of the latest advances in immunotherapy emerging from the 2026 AACR Annual Meeting, April 17–22, 2026. (Thanks to Jennifer Anderson, MD, PhD and Terri Holzen, PhD for compiling these scientific highlights) Phase 1 study of GV20-0251, a human antibody against the novel immune checkpoint IGSF8, for solid tumors CT001. Evaluation of pharmacodynamic and potential predictive biomarkers for GV20-0251, an anti-IGSF8 antibody, as monotherapy from ongoing Phase 1/2a study Xingfeng Bao (GV20 Therapeutics LLC, Newton, MA, USA) presented an ongoing phase 1/2a study of GV20-0251, a human antibody targeting the novel ...

JITC Digest April 2026

By JITC Publications posted 04-15-2026

INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks| JITC Meet-the-Editor Session at AAI| Popular Archive Articles Letter from the Editor Hello JITC Readers, As the spring opens up with a series of meetings arising, including the recent WIC-APAC (World Immunotherapy Council Asia-Pacific in Taiwan), the annual AAI (American Association of Immunology in Boston April 15-19), where I will be holding meet-the-editor sessions on both Thursday, April 16, and Friday, April 17, at the SITC booth (see the special feature below for more details), this year’s AACR (American Association of Cancer ...

Immune Monitor - March 2026

By SITC Communications posted 03-27-2026

A Message from the President One of the most impactful ways the Forward Fund supports early-career investigators is through its fellowship program . These awards provide critical funding and mentorship to help launch independent research careers in immuno-oncology. Since 2014, these fellowships have provided $6.32 million in fellowship awards. Letters of intent for fellowship applications are due April 15 , and I encourage eligible members to consider applying and to share this opportunity with trainees and colleagues. We are also excited to announce that applications are open for the 2026 Women in Cancer Immunotherapy Network Leadership Institute ...

SITC Publishes Renal Cell Carcinoma Clinical Practice Guideline version 3.0

By Thomas Martin posted 03-25-2026

The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a guideline update, “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0” in the Journal for ImmunoTherapy of Cancer ( JITC ). The RCC treatment landscape has evolved considerably since the previous publication of SITC’s RCC guideline in 2019. Immune checkpoint inhibitor (ICI) therapy is now approved in the adjuvant setting and is a treatment option for patients with resectable RCC at high risk for recurrence. Furthermore, additional ICI-based combination therapies have since ...

SITC Publishes Expert Insights on ICI-Related irAE Survivorship Care

By JITC Publications posted 03-23-2026

The Society for Immunotherapy of Cancer is pleased to announce the publication of a new article, “ Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: Expert insights from SITC on survivorship care and the need for long-term data ” in the Journal for ImmunoTherapy of Cancer . Over the past two decades, immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, providing durable disease control for many patients. Thanks to an increasing number of ICIs approved for new diseases and in earlier disease states, there is a growing population of survivors with a history of ICI treatment. Unfortunately, these ...

Oncology News Burst from the FDA: FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma

By SITC Communications posted 03-23-2026

In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

JITC Digest March 2026

By JITC Publications posted 03-18-2026

INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks|Special Series: SITC 40 th Anniversary| Popular Archive Articles Letter from the Editor Hello JITC Readers, We are quite fortunate to have several philanthropic agencies supporting and promoting the development of novel therapies in the IO space. These include the recent fundraiser for the Emily Whitehead Foundation that I was privileged to attend as part of the G-Rex® Grant Tour at The Franklin Institute in Philadelphia last month. The Foundation provides counseling and support to families preparing for cell therapy, while promoting ...